CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia ; day:07 ; month:03 ; year:2022 ; extent:23
EMBO molecular medicine / European Molecular Biology Organization ; (07.03.2022) (gesamt 23)
- Urheber
-
He, Lixiazi
Arnold, Christian
Thoma, Judith
Rohde, Christian
Kholmatov, Maksim
Garg, Swati
Hsiao, Cheng‐Chih
Viol, Linda
Zhang, Kaiqing
Sun, Rui
Schmidt, Christina
Janssen, Maike
MacRae, Tara
Huber, Karin
Thiede, Christian
Hébert, Josée
Sauvageau, Guy
Spratte, Julia
Fluhr, Herbert
Aust, Gabriela
Müller‐Tidow, Carsten
Niehrs, Christof
Pereira, Gislene
Hamann, Jörg
Tanaka, Motomu
Zaugg, Judith B.
Pabst, Caroline
- DOI
-
10.15252/emmm.202114990
- URN
-
urn:nbn:de:101:1-2022030714075820918979
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- He, Lixiazi
- Arnold, Christian
- Thoma, Judith
- Rohde, Christian
- Kholmatov, Maksim
- Garg, Swati
- Hsiao, Cheng‐Chih
- Viol, Linda
- Zhang, Kaiqing
- Sun, Rui
- Schmidt, Christina
- Janssen, Maike
- MacRae, Tara
- Huber, Karin
- Thiede, Christian
- Hébert, Josée
- Sauvageau, Guy
- Spratte, Julia
- Fluhr, Herbert
- Aust, Gabriela
- Müller‐Tidow, Carsten
- Niehrs, Christof
- Pereira, Gislene
- Hamann, Jörg
- Tanaka, Motomu
- Zaugg, Judith B.
- Pabst, Caroline
Ähnliche Objekte (12)
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia
Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Identifying mechanisms of resistance to BCL2 inhibitor venetoclax in acute myeloid leukemia (AML)
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
The combination of venetoclax and quercetin exerts a cytotoxic effect on acute myeloid leukemia
Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia